Gene Yoshikawa
Internal Medicine · Torrance, CANPI 1710447628
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,005, 7.3 times the $138 reported in 2019.
Across 75 payments — averaging $33.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$331
- Johnson & Johnson$239
- Genentech USA, Inc.$209
- Exelixis Inc.$175
- E.r. Squibb & Sons, L.L.C.$148
- EMD Serono, Inc.$116
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,34292%
- Education$1908%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 6 | $331 |
| Johnson & Johnson | 6 | $239 |
| Genentech USA, Inc. | 4 | $209 |
| Exelixis Inc. | 1 | $175 |
| E.r. Squibb & Sons, L.L.C. | 6 | $148 |
| EMD Serono, Inc. | 3 | $116 |
| Jazz Pharmaceuticals Inc. | 3 | $102 |
| Incyte Corporation | 3 | $84 |
| Karyopharm Therapeutics Inc. | 3 | $82 |
| Springworks Therapeutics, Inc. | 2 | $70 |
| Gilead | 2 | $65 |
| AVEO Pharmaceuticals, Inc. | 2 | $64 |
| Amgen(2 entities) | 4 | $62 |
| ADC Therapeutics America, Inc. | 2 | $60 |
| Bristol Myers Squibb | 2 | $59 |
| Astellas Pharma US Inc | 2 | $57 |
| Sanofi | 2 | $55 |
| AbbVie | 2 | $44 |
| Mirati Therapeutics, Inc. | 2 | $44 |
| Beone Medicines USA, Inc. | 1 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Syndax Pharmaceuticals, Inc. | 1 | $32 |
| Novartis | 1 | $31 |
| Pharmaessentia USA Corporation | 1 | $31 |
| Beigene USA, Inc. | 1 | $29 |
| X4 Pharmaceuticals, Inc. | 1 | $28 |
| Array Biopharma Inc | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Taiho Oncology, Inc. | 1 | $26 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Geron Corporation | 1 | $24 |
| Bayer | 1 | $23 |
| Biogen | 1 | $20 |
| Boehringer Ingelheim | 1 | $15 |
| CTI Biopharma Corp. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,532 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 11 | $231,640 |
| Anastrozole | 20 | $243 |
| Dexamethasone | 16 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $148 | $231,64011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Torrance
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.